<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04630223</url>
  </required_header>
  <id_info>
    <org_study_id>EndocanIUGR</org_study_id>
    <nct_id>NCT04630223</nct_id>
  </id_info>
  <brief_title>Levels of Endocan in Umbilical Cord Blood Samples of Pregnant Females With Intrauterine Growth Retardation</brief_title>
  <official_title>Comparison of Umbilical Cord Blood Levels of Endocan in Pregnant Females With and Without Intrauterine Growth Retardation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Van Bölge Eğitim ve Araştırma Hastanesi</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Van Bölge Eğitim ve Araştırma Hastanesi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      As a proteoglycan secreted from endothelial cells, expression, and secretion of endocan&#xD;
      increases in the endothelium of several tissues secondary to inflammation. It can be regarded&#xD;
      as an indicator of endothelial damage. Besides, it is both a target and a modulator of the&#xD;
      vascular endothelial growth factor (VEGF) signaling pathway. Considering its action&#xD;
      mechanisms, it can provide information about angiogenesis, inflammation, and vascular&#xD;
      permeability.&#xD;
&#xD;
      It is known that intrauterine growth retardation mainly occurs as a result of endothelial&#xD;
      dysfunction and abnormal angiogenesis in the placenta. In previous studies, maternal serum&#xD;
      endocan levels have also been shown to be increased in cases of preeclampsia, which is mainly&#xD;
      characterized by placental dysfunction.So, we hypothesize that there may be an association&#xD;
      between endocan levels and intrauterine growth retardation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Endocan is a proteoglycan that is closely associated with inflammation. Its levels increase&#xD;
      in association with the severity of endothelial damage. Endothelial dysfunction and abnormal&#xD;
      angiogenesis in the placental tissues are the main pathophysiological mechanisms leading to&#xD;
      intrauterine growth retardation.&#xD;
&#xD;
      It has been known that there was a significant association between maternal serum levels of&#xD;
      endocan and preeclampsia. In cases with preeclampsia, increased serum levels of endocan in&#xD;
      maternal blood samples has been reported.&#xD;
&#xD;
      Intrauterine growth retardation is a situation in which endothelial dysfunction and abnormal&#xD;
      angiogenesis are the leading disturbances. In fetuses with intrauterine growth retardation, a&#xD;
      hypoxic environment secondary to uteroplacental insufficiency. In previous studies, increased&#xD;
      levels of endocan in maternal blood samples have been shown. Although maternal blood can be a&#xD;
      good reflector of situations both in fetuses and their mothers, measurement of endocan in&#xD;
      umbilical cord blood samples may better represent the pathology in fetuses.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 1, 2020</start_date>
  <completion_date type="Actual">September 30, 2020</completion_date>
  <primary_completion_date type="Actual">September 1, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>endocan in umbilical cord blood</measure>
    <time_frame>just after delivery of fetus at clamping of umbilical cord</time_frame>
    <description>levels of endothelial cell specific molecule 1 (ng/ml) in umbilical cord blood</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">100</enrollment>
  <condition>Intrauterine Retardation</condition>
  <arm_group>
    <arm_group_label>intrauterine growth retardation</arm_group_label>
    <description>Blood samples are going to be taken from the umbilical cord of the fetuses. Levels of endocan (endothelial cell specific molecule 1) in the samples of umbilical cord blood are going to be measured using human endocan ELISA kits.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>healthy fetuses</arm_group_label>
    <description>Blood samples are going to be taken from the umbilical cord of healthy fetuses without intrauterine growth retardation. Levels of endocan (endothelial cell specific molecule 1) in the samples of umbilical cord blood are going to be measured using human endocan ELISA kits.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>endocan in umbilical cord blood</intervention_name>
    <description>After taking blood samples from the umbilical cord, centrifugation is applied to all samples for 15 minutes at 1000 rpm. The serum samples with specific identification numbers are going to be stored at -80 °C. After completing the study group, all serum samples will be analyzed using human endocan ELISA kit for the measurement of endocan levels.</description>
    <arm_group_label>healthy fetuses</arm_group_label>
    <arm_group_label>intrauterine growth retardation</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Pregnant females attending outpatient clinics of obstetrics in a tertiary hospital.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        For &quot;intrauterine growth retardation&quot; group:&#xD;
&#xD;
          -  consent to participate study&#xD;
&#xD;
          -  detection of intrauterine growth retardation during follow up of pregnancy&#xD;
&#xD;
        For &quot;healthy fetuses&quot; group:&#xD;
&#xD;
          -  consent to participate study&#xD;
&#xD;
          -  absence of intrauterine growth retardation during follow up of pregnancy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  multiple pregnancy&#xD;
&#xD;
          -  presence of major developmental anomalies of fetuses&#xD;
&#xD;
          -  detection of chromosomal anomalies&#xD;
&#xD;
          -  malnourished mothers&#xD;
&#xD;
          -  vegetarian diet of mothers&#xD;
&#xD;
          -  use of cigarette and alcohol during pregnancy&#xD;
&#xD;
          -  previous history of stillbirths&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>female pregnants</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Van Region Education and Training Hospital</name>
      <address>
        <city>Van</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <results_reference>
    <citation>Kucukbas GN, Kara O, Yüce D, Uygur D. Maternal plasma endocan levels in intrauterine growth restriction. J Matern Fetal Neonatal Med. 2020 Apr 14:1-6. doi: 10.1080/14767058.2020.1749591. [Epub ahead of print]</citation>
    <PMID>32290736</PMID>
  </results_reference>
  <results_reference>
    <citation>Lan X, Liu Z. Circulating endocan and preeclampsia: a meta-analysis. Biosci Rep. 2020 Jan 31;40(1). pii: BSR20193219. doi: 10.1042/BSR20193219.</citation>
    <PMID>31854443</PMID>
  </results_reference>
  <results_reference>
    <citation>Szpera-Gozdziewicz A, Kosicka K, Gozdziewicz T, Krzyscin M, Wirstlein P, Siemiatkowska A, Glowka F, Wender-Ozegowska E, Breborowicz GH. Maternal Serum Endocan Concentration in Pregnancies Complicated by Intrauterine Growth Restriction. Reprod Sci. 2019 Mar;26(3):370-376. doi: 10.1177/1933719118773480. Epub 2018 May 9.</citation>
    <PMID>29742984</PMID>
  </results_reference>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 9, 2020</study_first_submitted>
  <study_first_submitted_qc>November 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 16, 2020</study_first_posted>
  <last_update_submitted>November 9, 2020</last_update_submitted>
  <last_update_submitted_qc>November 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Van Bölge Eğitim ve Araştırma Hastanesi</investigator_affiliation>
    <investigator_full_name>cagdas özgökce</investigator_full_name>
    <investigator_title>MD, specialist on obstetrics and gynecology</investigator_title>
  </responsible_party>
  <keyword>intrauterine growth retardation</keyword>
  <keyword>umbilical cord blood</keyword>
  <keyword>proteoglycans</keyword>
  <keyword>pregnancy outcomes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fetal Growth Retardation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Medical data of the participants are going o be shared if it is requested.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

